{
    "nct_id": "NCT04853017",
    "official_title": "First in Human Phase 1 Trial of ELI-002 Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS) Mutated Pancreatic Ductal Adenocarcinoma and Other Solid Tumors",
    "inclusion_criteria": "* KRAS/NRAS mutated (G12D or G12R) solid tumor\n* Positive for circulating tumor DNA (ctDNA) and/or elevated serum tumor biomarker despite prior standard therapy including surgery and chemotherapy/radiation therapy where applicable\n* Screening CT is negative for recurrent disease\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Presence of tumor mutations where specific therapy is approved, and the patient is able to receive the approved therapy\n* Known brain metastases\n* Use of immunosuppressive drugs",
    "miscellaneous_criteria": ""
}